# MK0752 in Treating Young Patients With Recurrent or Refractory CNS Cancer

> **NCT00572182** · PHASE1 · TERMINATED · sponsor: **Pediatric Brain Tumor Consortium** · enrollment: 33 (actual)

## Conditions studied

- Brain and Central Nervous System Tumors

## Interventions

- **DRUG:** MK-0752

## Key facts

- **NCT ID:** NCT00572182
- **Lead sponsor:** Pediatric Brain Tumor Consortium
- **Sponsor class:** NETWORK
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-07
- **Primary completion:** 2011-02
- **Final completion:** 2011-02
- **Target enrollment:** 33 (ACTUAL)
- **Why stopped:** This Phase I study was permanently closed to patient accrual on February 23, 2011, due to the discontinuation of support from MERCK.
- **Last updated:** 2012-03-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00572182

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00572182, "MK0752 in Treating Young Patients With Recurrent or Refractory CNS Cancer". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00572182. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*